“A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC#725085 Alliance IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)”
Study Objective: The primary objective of the study is to determine whether there is an overall survival advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of progression, in comparison with bevacizumab alone in patients with surgically resectable recurrent glioblastoma multiforme.
Arm 1: Vaccine + bevacizumab
Arm 2: Vaccine, bevacizumab at progression
Arm 3: Bevacizumab
Principal Investigator: Anthony D'Ambrosio, M.D.
Click here for more information on A071101
"Randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed GBM with MGMT promoter hypermethylation"
Study Objective: Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ (temozolomide), compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed glioblastoma multiforme (GBM) patients with tumor O-6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter hypermethylation.
Arm 1: Chemo + veliparib (investigational PARP inhibitor)
Arm 2: Chemo + placebo
The Valley Hospital Biorepository
For The Valley Hospital (TVH) patients undergoing surgical procedures, we offer the opportunity to participate in TVH Biorepository. This protocol involves the freezing and storage of extra tissue not used for diagnosis, blood and other bodily fluids that may be used for future research designed to develop or contribute to generalized knowledge in cancer research. Available to all persons diagnosed with cancer, having surgery for excision, and is strongly encouraged.